Amerise biosciences Limited has announced key changes in its management structure, with the resignation and appointment of Company Secretary & Compliance Officer positions taking effect simultaneously on April 15, 2026. The company has informed BSE Limited about these changes in compliance with SEBI regulations.

Management Transition Details

The company has experienced a complete transition in its Company Secretary role, with both resignation and appointment occurring on the same date to ensure operational continuity.

Resignation of Ms. Minal Lakhani

Ms. Minal Lakhani has tendered her resignation from the position of Company Secretary & Compliance Officer due to personal reasons. Her resignation has been accepted by the company, and she will be relieved from all duties and responsibilities effective April 15, 2026. In her resignation letter dated April 14, 2026, Ms. Lakhani confirmed her commitment to extend full cooperation for smooth transition and proper handover of statutory records and documents as required under applicable laws.

Appointment of Ms. Soni Pandiya

Ms. Soni Pandiya has been appointed as the new Company Secretary & Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. She brings significant expertise to the role with her professional qualifications and experience.

Regulatory Compliance

The company has made these disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III to the Listing Regulations. All required documentation and annexures have been submitted to BSE Limited as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015. The notification was signed by Albert Hines, Wholetime Director of the company, ensuring proper authorization of the management changes.

Amerise biosciences Limited has officially notified BSE Limited that it is not required to submit the Annual Secretarial Compliance Report under SEBI regulations, citing specific exemptions based on its financial parameters. The company communicated this development through a formal letter dated 09.04.2026.

Regulatory Exemption Details

The company has claimed exemption under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. According to this regulation, corporate governance provisions do not apply to listed entities having paid-up equity share capital not exceeding Rs. 10 crores and net worth not exceeding Rs. 25 crores as on the previous financial year.

Amerise Biosciences stated that the Annual Secretarial Compliance Report under Regulation 24A of SEBI (LODR) Amendment Regulations, 2018, read with BSE Circular dated 9th May, 2019, is not applicable to the company due to this exemption.

Financial Parameters Certification

Practicing Company Secretary Daksha Negi has provided certification confirming the company's eligibility for exemption. The certification details the company's financial position across three consecutive financial years:

The certification confirms that both paid-up capital and net worth remained well below the regulatory thresholds throughout the specified period.

Compliance Framework

The exemption specifically relates to Regulation 27(2) of SEBI (LODR) Regulations, 2015, read with Regulation 15(2)(a) of Chapter IV. The practicing company secretary's certificate, issued from Ahmedabad on 08.04.2026, formally validates that these provisions are not mandatory for Amerise Biosciences Limited.

The company, formerly known as Amradeep Industries Limited, operates under CIN L29199GJ1984PLC007195 and has requested BSE to take this exemption status on record. This regulatory communication ensures transparency regarding the company's compliance obligations while maintaining adherence to applicable SEBI guidelines.